肺泡表面活性物质已成功地应用于早产儿呼吸窘迫综合征的治疗,该文旨在观察它对足月新生儿呼吸衰竭的疗效。病人及方法研究对象的标准为(1)患有肺炎、胎粪吸入综合征、败血症或窒息的足月儿;(2)吸入氧浓度(FiO_2)≥0.5;(3)平均气道压力(MAP)≥7cmH_2O。该组14例病人全部接受小牛肺表面活性物质提取 Alveolar surfactant has been successfully used in the treatment of respiratory distress syndrome in preterm infants, and this article aims to observe its efficacy in term neonatal respiratory failure. Patients and Methods Subjects were screened for (1) term infants with pneumonia, meconium aspiration syndrome, sepsis or asphyxia; (2) FiO 2 ≥ 0.5; (3) mean airway pressure ) ≥7cmH_2O. The group of 14 patients all received calf pulmonary surfactant extraction